What is the outlook for the US Biopharma industry?
The United States Biopharmaceutical industry is widely envied around the world, and for good reason. From gene editing, to cell-based therapies, to profoundly new ways of manipulating immune cells to target cancers, today’s science is being translated into practical treatments for patients at breakneck speed. Biopharma companies have achieved remarkable progress in advancing early disease detection and enabling targeted treatments with limited side effects.
These innovations have catalyzed significant reductions in the number of deaths due to cancer, HIV/AIDS, and autoimmune diseases across the world. This provides reasons for optimism that America’s dynamic life sciences industry will be able to collectively rise to the occasion and defeat the novel COVID-19 virus that is bedeviling society today. As we move through these uncertain times, it is crucial for investors, pharmaceutical executives, and scientific researchers involved in the US biopharmaceutical industry to remain together and informed. The way in which groups across industry, academia, government, and the broader health-care system have come together to fight this pandemic have been inspiring. Indeed, continuing to partner in this way will be critical in successfully navigating public health challenges of the future.
The following report, a Global Business Reports and CPhI collaboration, offers widespread coverage of the state of the US biopharmaceutical industry, including big pharma and its blockbuster drugs, emerging biotech and their innovative drug pipelines, and the different service providers across the value chain, from CDMO’s and CRO’s to AI and big data platform companies.